Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Abroad (travel likely)RecruitingPHASE2

Conditions

Brain Metastases · Nonsmall Cell Lung Cancer Stage III

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Contact: Study coordinator (Study Nurse) · 336-713-7748
Contact: Principal Investigator (Michael Farris, MD)

Study leads

Michael Farris, MD
Principal Investigator
Wake Forest Baptist Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Melanoma · Brain Metastases

Abroad (travel likely)RecruitingPHASE2

Palo Alto, United States

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

NSCLC · Brain Metastases · ROS1 Gene Rearrangement

Abroad (travel likely)RecruitingPHASE2

Graz, Austria · Vienna, Austria

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

Brain Metastases · Brain Cancer

Abroad (travel likely)RecruitingPHASE2

Miami, United States